Henry Ford Health

Henry Ford Health Scholarly Commons
Dermatology Articles

Dermatology

5-1-2021

50 Years of Topical Retinoids for Acne: Evolution of Treatment
Hilary Baldwin
Guy Webster
Linda F. Stein Gold
Henry Ford Health, lstein1@hfhs.org

Valerie Callender
Fran E. Cook-Bolden

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_articles

Recommended Citation
Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, and Guenin E. 50 Years of Topical
Retinoids for Acne: Evolution of Treatment. Am J Clin Dermatol 2021; 22(3):315-327.

This Article is brought to you for free and open access by the Dermatology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Dermatology Articles by an authorized administrator of Henry Ford
Health Scholarly Commons.

Authors
Hilary Baldwin, Guy Webster, Linda F. Stein Gold, Valerie Callender, Fran E. Cook-Bolden, and Eric Guenin

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
dermatology_articles/567

American Journal of Clinical Dermatology (2021) 22:315–327
https://doi.org/10.1007/s40257-021-00594-8

REVIEW ARTICLE

50 Years of Topical Retinoids for Acne: Evolution of Treatment
Hilary Baldwin1,2 · Guy Webster3 · Linda Stein Gold4 · Valerie Callender5,6 · Fran E. Cook‑Bolden7 · Eric Guenin8
Published online: 19 April 2021
© The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021

Abstract
Since the US Food and Drug Administration (FDA) approved tretinoin in 1971, retinoids alone or combined with other agents
have become the mainstay of acne treatment. Retinoids act through binding to retinoic acid receptors, altering expression
levels of hundreds of cellular proteins affecting multiple pathways involved in acne pathogenesis. Retinoids have evolved
from first-generation agents, such as tretinoin, through chemical modifications resulting in a second generation (etretinate
and acitretin for psoriasis), a third generation (adapalene and tazarotene) and, most recently, a fourth (trifarotene). For all
topical retinoids, local irritation has been associated with poor tolerability and suboptimal adherence. Efforts to improve tolerability have utilized novel delivery systems and/or novel agents. This qualitative literature review summarizes the evolution
of the four topical single-agent retinoids available for the treatment of acne in the US today and their various formulations,
presenting the rationale behind their development and data from key studies.

1 Introduction
In 1971, the US Food and Drug Administration (FDA)
granted approval of the first topical retinoid, tretinoin 0.05%
solution (also: all-trans retinoic acid [ATRA]; vitamin A
acid), for use in acne vulgaris [1]. In the years that followed,
novel retinoids, formulations, and combinations were introduced to improve efficacy and tolerability. Today, topical
retinoids, either alone or in combination with benzoyl peroxide or topical antibiotics, are the mainstay of acne therapy
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Key Points
Topical retinoids—alone or in combination with other
agents—have become the mainstay of acne treatment in
the 50 years since the initial approval of tretinoin.
The local irritation associated with topical retinoids,
which is most prominent in the first few weeks of therapy, has been associated with poor treatment adherence.
Further research has resulted in new generations and
formulations of retinoids with improved stability and
greater tolerability, which offer today’s clinical dermatologists better options for ensuring patient adherence
and consequently treatment success.

[2–6]. They are strongly recommended for acne management and treatment by the American Academy of Dermatology based on consistent, good-quality, patient-oriented
evidence [5]. In addition, topical retinoids have provided
treatment options in other dermatological conditions including atrophic scarring [7], postinflammatory hyperpigmentation [8], photodamaged skin [9], and melasma [10]. In this
qualitative literature review, we focus on key aspects of the
50-year evolution of single-agent topical retinoids specifically for the treatment of acne vulgaris.
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Acne pathology and the mechanisms of action of retinoids are complex and multifactorial. Major factors in acne
pathogenesis include epithelial hyperproliferation, increased
sebum production with concurrent alterations in its composition, increased Cutibacterium acnes population, and follicular and perifollicular inflammation [11]. These can impair
normal functioning of the pilosebaceous unit, leading to the
formation of microcomedones, comedones, inflammatory
lesions, or nodules.
Retinoids, analogs of vitamin A, have pleiotropic effects
including comedolysis and reduction of microcomedonal
formation. They have been shown to benefit both comedonal
and inflammatory acne [12, 13]. The mechanisms through
which these effects occur are believed to involve binding
to retinoic acid receptors (RARs). Three subtypes, RAR-α,
RAR-β, and RAR-γ, are known, of which RAR-γ expression
is highest in human skin [14, 15]. Different retinoids vary
in their receptor subtype affinity and may be more selective
for one receptor versus another. The hypothesis that receptor
subtype selectivity might improve topical retinoid efficacy
and/or tolerability fueled the search for, and eventual discovery of, subtype-selective retinoids. However, no evidence
exists to suggest that retinoid receptor subtypes influence
efficacy or tolerability. Indeed, some retinoids have the same
receptor binding yet differ in potency and tolerability.
Tretinoin, the principle active metabolite of vitamin A,
binds with similar affinity to all three subtypes, but binding to RAR-γ is key to its effects. This binding activates the
RAR-γ complex with the retinoid X receptor (RXR)-α [16,
17]. The activated complex in turn binds to specific DNA
promoter sequences known as retinoic acid response elements
(RAREs), stimulating gene transcription through transactivation and resulting in activation of more than 300 genes that
alter expression levels of hundreds of proteins [16, 18].
Tretinoin also exerts indirect effects on DNA lacking RAREs through downregulation of pro-inflammatory
nuclear transcription factors such as AP-1, which normally
upregulates the matrix metalloproteases responsible for acne
scar formation [19]. The direct and indirect effects of retinoids result in inhibition of leukocyte migration, cytokine
production, and arachidonic acid metabolism, as well as
downregulation of toll-like receptor (TLR) activation. Collectively, these effects reduce inflammation, which is now
increasingly recognized as a common feature of all acne
lesions, whether clinically inflamed or not [11, 19].

2 Evolution of Topical Retinoids for Acne
2.1 First‑ and Second‑Generation Retinoids
The effects of tretinoin on acne were first described in
1969 [20]. Two years later, it became the first retinoid to be
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approved for use in treating acne by the US FDA (Fig. 1) [1].
Tretinoin, along with its 13-cis-retinoic acid isomer isotretinoin (FDA approved only for oral use in acne) and its 9-cisretinoic acid isomer alitretinoin (used in treating Kaposi’s
sarcoma)—all metabolites of vitamin A—constitute the first
generation of clinically useful retinoids [21].
Tretinoin, as originally approved, had room for improvement. Irritation at the application site—now believed to
be due in large part to the hydroalcoholic vehicle used in
the original formulation—was pronounced [22] and led to
speculation that retinoid efficacy went hand-in-hand with
irritation [23]. In addition, tretinoin in the original formulation was unstable when exposed to light and oxygen [18],
which led to limitation of daytime use. Chemically, the
long polyene sidechain of tretinoin provides the flexibility
to adopt multiple configurations, some of which can bind
to receptors other than its target [24]. It could also isomerize to 9-cis-retinoic acid, a ligand for RXRs. Replacing the
flexible polyene sidechain with more rigid ones could therefore benefit both stability and selectivity, the latter of which
might be expected to translate into better tolerability and/
or efficacy [24]. After a second generation of retinoids was
produced by modification of the cyclic end group, resulting
in the systemic drugs etretinate and acitretin for the treatment of psoriasis [24–26], a third generation of retinoids
was produced by replacing the polyene sidechain with rigid,
aromatic structures.

2.2 Third‑Generation Retinoids
In 1996, topical adapalene 0.1% became the first of these
conformationally rigid, third-generation compounds to be
approved for the treatment of acne (Fig. 1) [27]. Although
adapalene acts primarily via RAR-γ, similar to tretinoin, the
structural and biochemical properties of these drugs vary
considerably. While tretinoin binds to RAR-α, RAR-β, and
RAR-γ as well as to cytosolic retinoic acid binding proteins (CRABPs), adapalene binds selectively to RAR-β and
RAR-γ only and is stable in the presence of light and benzoyl
peroxide [18, 28]. Furthermore, the percutaneous absorption
of topical adapalene appeared to be considerably less than
that of tretinoin [29, 30], which could be beneficial if irritation were caused by excess absorption [31]. Adapalene was
specifically engineered to a particle size of 3–10 microns to
allow preferential delivery into hair follicles [18]. As comparative studies of adapalene and tretinoin demonstrated
varying results, a meta-analysis of five clinical studies with
900 patients with mild-to-moderate acne was conducted to
compare adapalene 0.1% gel with tretinoin 0.025% gel [32].
There were no significant differences between these agents
at week 12 in reduction of inflammatory, noninflammatory,
or total lesion counts. However, adapalene demonstrated
superior local tolerability over tretinoin (overall mean side
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Fig 1  Timeline of FDA approval dates for single-agent topical retinoid formulations for the treatment of acne (Source: www.accessdata.
fda.gov/scripts/cder/daf). *First approval for the active ingredient. All
other dates shown are for the first approval of new formulation (e.g.,

gel, cream, lotion) or new concentration. Colors indicate type of retinoid. Note: Some formulations shown may be discontinued or may be
sold as generics or under different brand names

effect score p < 0.001). Although the basis for this superior
tolerability was never elucidated, at the time many attributed
it to the RAR-β/γ subtype selectivity of adapalene, further
fueling the search for other selective retinoids.
Shortly after the approval of adapalene, another conformationally rigid, third-generation retinoid, tazarotene
gel (0.1%), was approved for use in mild-to-moderate acne
in 1997 (Fig. 1) [33]. Tazarotene is an ethyl ester prodrug
that is converted to the active component, tazarotenic acid.
Molecular features were introduced to avoid accumulation
of the compound or its metabolites in fatty tissue and ensure
rapid systemic elimination [24]. Like adapalene [28], tazarotene is stable to UV light [34] and its metabolite, tazarotenic
acid, binds RAR-β and RAR-γ, but not RAR-α or RXRs
[24]. A multicenter, double-blind, randomized trial comparing once-daily tazarotene 0.1% gel to once-daily tretinoin
0.025% gel in 143 patients with mild-to-moderate facial
acne found that tazarotene was significantly more effective
in reducing noninflammatory lesion counts (p ≤ 0.05) and
numerically more effective in reducing the total inflammatory lesion count [35]. At week 4, however, tazarotene was
associated with more peeling, dryness, and burning than
tretinoin (p < 0.05). Another multicenter randomized trial
over 12 weeks compared once-daily tazarotene 0.1% gel and
once-daily adapalene 0.1% gel in patients with mild-to-moderate facial acne [36]. Tazarotene was associated with significantly greater treatment success (78% vs 52%; p < 0.05)
and reductions in severity, noninflammatory lesion count,
and inflammatory lesion count than adapalene (p < 0.05,
all). Tazarotene, however, was significantly associated with
transiently greater levels of burning, pruritis, and erythema
than adapalene at week 4 (p < 0.01) and greater levels of
peeling at weeks 4 and 8 (p < 0.05). Interestingly, another

12-week study comparing once-daily tazarotene 0.1% cream
with once-daily adapalene 0.1% cream found that tazarotene provided a significantly greater treatment success rate
(77% vs 55%; p ≤ 0.01) and a significantly greater reduction
in comedone count (p ≤ 0.001), with peeling and burning
scores that were significantly higher than those for adapalene
at weeks 4 and 8, but not significantly different at week 12
[37]. When considered in light of the previously described
tazarotene studies, the tolerability results cast doubt on the
hypothesis that receptor subtype specificity alone could
explain retinoid tolerability.
Although few studies have compared these three agents,
one retrospective study used clinician evaluations of patient
photographs from seven phase IV, randomized, doubleblind, parallel-group studies of tazarotene (0.1% gel and
0.01% cream), adapalene 0.1% gel, or tretinoin (0.1% microsponge and 0.025% gel) [13]. Photographs were assessed for
clinically meaningful (1-grade improvement on a 7-point
severity scale) and clinically significant (≥ 2-grade improvement) changes in inflammatory acne severity after 12 or 15
weeks of treatment [13]. Overall, a higher proportion of retinoid-treated participants showed clinically meaningful and
clinically significant improvements versus vehicle-treated
participants (p ≤ 0.001, both). When comparing active treatments, tazarotene 0.1% gel showed greater clinically significant improvements compared with adapalene 0.1% gel
(p ≤ 0.001) and tretinoin 0.025% gel (p ≤ 0.01), but not
tretinoin 0.01% microsponge. Caution must be taken, however, when interpreting these results due to the retrospective
nature of the study.
Recently, a systematic review also compared these three
agents and concluded that tretinoin (0.05% cream and 0.04%
and 0.1% microsphere) worked more rapidly than tazarotene
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(0.1% foam and 0.1% cream) in reducing inflammatory
lesions and that adapalene (0.1% lotion and 0.1% and 0.3%
gel) was better tolerated than tazarotene and tretinoin [38].
A major caveat to this interpretation, however, is that a wide
variety of concentrations and formulations of all three agents
(some in trials designed to establish non-inferiority) were
included, leaving the relevance to any particular comparison
open to question. Adapalene has often been considered the
best tolerated but also the least effective of these three retinoids, while tazarotene has been considered the most efficacious but least well tolerated [22, 39]. However, factors such
as retinoid concentration and vehicle formulation (discussed
subsequently) can also affect tolerability and efficacy [2, 40].

2.3 Fourth‑Generation Retinoids
The most recently approved topical retinoid for acne treatment is the fourth-generation, first-in-class, purely RAR-γ
selective agent trifarotene 0.005% cream [41]. Approved in
2019 for acne treatment (Fig. 1), it was designed to be stable in keratinocytes but rapidly metabolized if systemically
absorbed. In the 12-week, double-blind, phase III PERFECT
1 and PERFECT 2 studies, a total of 2420 patients with
moderate facial and truncal acne received either once-daily
trifarotene 0.005% cream or vehicle for 12 weeks [42]. Rates
of success (clear or almost clear skin at week 12) and reductions in inflammatory and noninflammatory lesion counts
were significantly higher with trifarotene than vehicle in
both studies (p < 0.05, all). The most common adverse
events (AEs) were application-site irritation (trifarotene vs
vehicle: 7.5% vs 0.3%) and application-site pruritis (2.4% vs
0.8%) [43]. Potent and selective binding to the RAR-γ receptor was thus efficacious but failed to completely abrogate the
skin irritation frequently observed with retinoid treatments.

3 Topical Retinoid Tolerability
and Adherence
Several skin reactions are commonly associated with irritation from topical retinoids, including dryness, erythema,
and peeling [44]. In 2015, Culp et al. examined the tolerability of topical retinoids in acne treatment by analyzing
data from 34 clinical studies that provided safety data for
tretinoin, adapalene, or tazarotene [44]. Table 1 summarizes
the incidence rates of AEs reported in those trials. Rates of
burning, irritation, erythema, and dry skin were remarkably
varied for the same retinoid in different study reports. For
example, incidence of erythema was reported to be 4.0% for
tazarotene foam 0.1% in one study and 95.0% for tazarotene
gel 0.1% in another [45, 46]. These data, however, are from
various concentrations and vehicle formulations for each
retinoid, and tolerability had been reported using different
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scales. Nonetheless, as has been observed across multiple
studies, AEs increase in severity with increasing retinoid
concentration regardless of vehicle or retinoid [38, 44]. Further, increases in mean scores for irritation, dryness, and
erythema were most frequent during the first few weeks of
treatment regardless of retinoid concentration and vehicle
formulation [42, 47]. This is believed to result from the process of normalizing desquamation in the epidermis, during
which corneocyte arrangement is disrupted and cohesion
is lost, leading to symptoms of irritation. After 1–2 weeks
of continued treatment, the rearrangement is complete and
irritation generally resolves [2].
A split-face study of retinoid tolerability in 253 healthy
volunteers, each using one of several topical retinoids (tazarotene, tretinoin, or adapalene) in various dosages/formulations, identified four factors influencing tolerability: retinoid
concentration, vehicle formulation, skin sensitivity, and the
specific retinoid [47]. Of these, skin sensitivity had the
greatest influence. Other factors that may influence tolerability include frequency of use, length of exposure, mode
of application, sun exposure, and the use of moisturizers
[48]. Additionally, a study of topical tretinoin identified the
concurrent use of other topical medications as a predictor of
increased AEs (odds ratio 1.88; p < 0.05) [49].
Tolerability is important for topical retinoids as the occurrence of side effects correlates with poor adherence, which
reduces response to treatment [50]. In 34 topical retinoid
clinical studies, only a small percentage of patients dropped
out [44], although it is possible that some who did not formally discontinue therapy may have reduced their medication usage. Furthermore, clinical study populations do not
represent real-world patient populations. In trials, carefully
standardized instructions are provided, frequent follow-up
visits encourage adherence, patients may be told they are
being monitored, and they are being paid to use medications
(which are provided at no cost) [44, 51]. These conditions
do not apply in clinical practice.
Medication adherence can refer to new prescriptions dispensed within a defined number of days after being ordered
or to having a prescription refilled within a defined number
of days [52], the latter of which could be affected by tolerability [53, 54]. Adherence (new prescription dispensed) to
topical and systemic acne medications was examined for
109 acne medications prescribed at a university dermatology
clinic; patients were queried by telephone [55]. The nonadherence rate for any topical medication was 13% and the
rate for topical retinoids was 30%. Cost and forgetfulness
were common, unprompted reasons given for nonadherence.
Adherence (medication consumed as estimated by prescription refills) to acne medications was also explored in a retrospective study of mostly young acne patients enrolled in
Medicaid [56]. This study assessed Medication Possession
Ratio (MPR), a metric calculated by dividing ‘the number
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Table 1  Incidence of adverse events for any single-agent topical retinoid formulation approved for acne
Retinoid

No. studies N

Skin burning (%) Cutaneous irritation (%) Erythema (%) Dry skin (%)

Tretinoin microsphere 0.1% gel [44]
Tretinoin microsphere 0.04% gel [44]
Tretinoin 0.05% gel [44]
Tretinoin 0.05% cream [44]
Tretinoin 0.025% gel [44]
Tretinoin 0.05% lotion [69]
Adapalene 0.1% gel [44]
Adapalene 0.3% gel [44]
Adapalene 0.1% cream [44]
Adapalene 0.1% lotion [44]
Tazarotene 0.1% gel [44]
Tazarotene 0.1% foam [44]
Tazarotene 0.1% cream [44]
Tazarotene 0.045% lotion [72]
Trifarotene 0.005% cream [43]

2
3
1
1
3
2a
3
2
2
2
1
1
2
2a
2a

7.7; 11
2.6; 2.1; 23.5
8
23/11b
1; 6; NR
< 1.0 [73]
5; NR; NR
30; 6
NR; 5
NR
NR
0; 2.0
1; 51
0 [74]
NR

78; 161
78; 55; 20
161
35
464; 635; 846
767
258; 85; 24
90; 261
130; 87
130; 533
24
373; 371
86; 90
779
1220

3.8; 23
6.4; 23.6; NR
5
NR
3; <1; NR
< 1.0 [73]
NR; 5; NR
NR
NR; 2
NR
NR
11.0; 18.0
2; NR
< 1.0 [74]
7.5

5.1; 5.0
1.3; 8.5; NR
5.0
65.7/45.7b
1.0; 5.0; NR
1.4c
NR; 6; 35.0
0; NR
NR; 2
NR
95.0
4.0; 9.0
6; 6
1.8c
NR

2.6; 32
2.6; 29.7; NR
14
11/23b
3; 8; <1
3.7c
7; 5; NR
0; 14
3; 8
4; 9
NR
8.0; 6.0
7; 7
3.6c
NR

Note: tolerability was reported using different terms and scales in different studies
Table adapted from the Culp et al. 2015 systematic review [44]; for three drugs approved after publication of the manuscript, results from pivotal
studies of those formulations have been added above
NR not reported
a

b
c

Two pooled studies
Split-face study where second value indicates tretinoin in conjunction with facial moisturizer
Treatment-related adverse events

of days of medication supplied within the refill interval’ by
‘the number of days in the refill interval’ [57]; an MPR of
1.0 indicates all medication was consumed. In patients aged
0–64 years (N = 24,438), of whom 89% were < 18 years
of age, the average MPR was 0.34 for all acne drugs and
0.31 for topical retinoids. For all acne drugs, only 11.7% of
patients were adherent (MPR ≥ 0.80) [56]. Reasons for nonadherence were not examined, but medication type (e.g., topical retinoids, oral antibiotics) affected adherence. Finally,
another study of 250 patients with acne (96% mild or moderate) who were prescribed topical medications found 54.4%
adherence (treatment not discontinued before the scheduled
time) [58]. Side effects were reported by 41.3% of the 75
patients treated with topical single-agent retinoids. Of the
patients on retinoid monotherapy who discontinued (n = 30),
50% discontinued due to side effects.

4 Improving Retinoid Tolerability
Several different approaches have been taken to improve
topical retinoid tolerability, including short contact therapy
and new vehicle formulations, which allow for lower-dose
formulations.

4.1 Short Contact Therapy
Short contact therapy minimizes the length rather than frequency of exposure through rinsing off the product after
an appropriate amount of time. In a multicenter, single-arm
study, tretinoin 0.05% cream applied once daily for 30 minutes for up to 32 weeks (mean treatment duration: 12 weeks)
was associated with efficacy similar to that of its standard
once-daily administration regimen, with better tolerability
(17.6% mild skin irritation, 5.4% discontinuation due to skin
irritation) [59]. Since skin irritation is greatest during the
first few weeks of therapy, short contact application of retinoids (30–60 min) has been recommended for the first 2–4
weeks to improve tolerability [2].

4.2 Non‑Daily Application
Topical retinoids for acne treatment are indicated for oncedaily use. In order to reduce the frequency of exposure,
however, retinoids could be applied every other day. In a
double-blind, randomized, parallel-group study, alternateday tazarotene 0.1% gel use was compared with once-daily
adapalene 0.1% gel in patients with mild-to-moderate acne
[60]. Both treatment regimens showed similar efficacy and
tolerability, indicating that alternate day use of tazarotene
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0.1% gel is as effective and may provide better tolerability
than once-daily use.

4.3 Role of Vehicle Formulation
Most research on improving the efficacy and tolerability of
topical retinoids has focused on the vehicle formulation [61].
The vehicle largely determines the absorption characteristics
of the topical agent and may itself modify cutaneous properties to allow penetration of the active ingredient. Furthermore, vehicles can be formulated to increase skin hydration
and decrease transepidermal water loss [62]. Vehicle optimization generally aims to ensure slow delivery of appropriate
amounts of retinoids specifically to their site of action, the
pilosebaceous unit, while reducing uneven drug distribution
and penetration into the deep epidermis and dermis [21].
Much of the evolution of topical retinoids has involved
improvements in vehicle, as can be seen in Table 2, which
summarizes efficacy data for currently approved topical
retinoid formulations for acne. Given that cross-trial comparisons are problematic due to factors such as differences
in study design and baseline patient populations, perhaps
the most notable trends are those towards larger trials with
stricter success criteria over time.
As indicated in Table 1, reported AE rates for a given
topical retinoid vary markedly, part of which undoubtedly
reflects dosage and formulation differences. Further, in addition to the caveats involved in cross-trial comparisons, the
wide variety of terms used to describe AEs and scales to
assess them over the 50-year history of retinoids confounds
attempts to dissect out formulation effects on tolerability for
a given retinoid except in head-to-head trials, few of which
have been reported.

4.4 Microsponge Delivery System
A number of novel retinoid formulations have been developed. One such formulation is the microsponge delivery system (MDS), where polymeric microspheres (5–300 microns
in diameter) with numerous interconnecting voids entrap the
active component and release it onto the surface of skin in
a controlled manner in response to rubbing, elevated temperature, or changes in pH (Fig. 2a) [62, 63]. MDS offers
potential advantages in improved stability, reduction in skin
oiliness through sebum absorption, and reduced irritation
by preventing uneven, locally high retinoid concentrations
(‘dumping’). A 12-week study of 360 patients with acne
who were treated with either MDS tretinoin gel 0.1% or
vehicle found significantly greater lesion reductions with
the MDS tretinoin formulation and transient mild to moderate irritation [64]. A split-face tolerance study of 25 patients
comparing the MDS tretinoin gel 0.1% to tretinoin gel 0.1%
reported 92% of patients preferred the MDS formulation for
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its mildness [64]. A meta-analysis of three randomized, double-blind, vehicle-controlled studies of MDS tretinoin 0.04%
in 629 patients with acne demonstrated significant superiority to vehicle in lesion reduction at 12 weeks, but erythema,
peeling, and dryness, albeit mostly mild, still occurred in
60–63% and 27–51% of patients in the MDS tretinoin and
vehicle arms, respectively [65]. Additionally, reductions in
oiliness and facial shine with MDS tretinoin gel have also
been documented in several studies [66]. The MDS formulations (tretinoin gel 0.04% and 0.1%) were approved for acne
treatment by the FDA in February 1997 (Table 2; Fig. 1).

4.5 Polyolprepolymer‑2
A gel formulation of polyolprepolymer-2 (PP-2) was
designed to allow the controlled, selective delivery of tretinoin to the skin, preventing too-rapid retinoid release. A
randomized, controlled trial compared the novel tretinoin gel
0.025% containing PP-2 with commercially available tretinoin gel 0.025% and vehicle in 215 patients with mild-tomoderate acne [67]. Both tretinoin formulations had similar
efficacy and were significantly better than vehicle on days
7, 56, and 84. However, the PP-2 formulation demonstrated
significantly less peeling than the commercial tretinoin gel
on days 28, 56, and 84; significantly less dryness by day
84; and significantly less itching on day 14. Burning and
erythema occurred less frequently with the PP-2 formulation than the commercial tretinoin gel at all assessment time
points, but the differences were not significant. The PP-2
formulation (tretinoin gel 0.025%) was FDA approved for
acne treatment in January 1998 (Table 2; Fig. 1).

4.6 Micronization and Polymeric Emulsion
Technology
As previously discussed, a sufficiently small particle size
allows better access to the pilosebaceous unit, the site of
action for topical retinoids. Micronization of tretinoin
0.05%—into particles predominately < 10 microns in diameter—resulted in better cutaneous tolerability and stability
in the presence of benzoyl peroxide and similar efficacy to
a microsphere formulation containing twice the concentration of tretinoin (0.1%) [68]. These tretinoin particles, as
well as moisturizers and hydrating ingredients, are dispersed
within a polymeric honeycomb matrix that provides a more
uniform distribution of all ingredients (Fig. 2b) [62]. This
formulation allows for the controlled and even release of
tretinoin into hair follicles with improved skin hydration.
Two 12-week, multinational, double-blind, phase III studies randomized a total of 1640 patients with moderate-tosevere acne to tretinoin lotion 0.05% or vehicle [69]. At
week 12, tretinoin lotion 0.05% proved superior to vehicle
in reducing inflammatory lesions (52% vs 41%; p < 0.001)

May 31, 1996

Adapalene gel
(Differin)
0.1%a
Agent
Vehicle
Tretinoin gel
(Retin-A
Micro) 0.1%
Agent
Vehicle
Tazarotene gel
(Tazorac)
0.1%a
Agent
Vehicle
Tretinoin
gel (Avita)
0.025%a
Agent
Vehicle
Adapalene cream
(Differin)
0.1%a
Agent
Vehicle
Tazarotene cream
(Tazorac) 0.1%
Agent
Vehicle
Tretinoin gel
(Retin-A
Micro) 0.04%
Agent
Vehicle
Adapalene gel
(Differin)
0.3%a

June 19, 2007

May 10, 2002

September 29,
2000

May 26, 2000

January 29, 1998

June 13, 1997

February 7, 1997

Approval date

Retinoid

NR
NR

71
67

149d
149d

58
58

175
175

206
205

111
103

261
134

72
72

150d
148d

198
204

119
118

218
218

108
110

NR
NR

20/53f
6/36f

19c
9c

18/55f
11/36f

14c
5c

NR
NR

NR
NR

NR
NR

18e
10e

28c
9c

35c
11c

38e
20e

NR
NR

Trial 2

16b
9b

Trial 1

Trial 1

Trial 2

Success (%)

N

−44
−13

−41g
−27g

−32
−17

−35
−25

−42
−30

−37
−18

−49.7
−40.7

Trial 1

−41
−30

−44g
−25g

−14
−6

−38
−23

−47
−28

−29
−24

NR
NR

Trial 2

Inflammatory lesion, mean %
reduction from BL

−37
2

−46g
−27g

−34
−18

−36
−27

−55
−35

−49
−22

−35.2
−27.2

Trial 1

−29
−14

−41g
−21g

−35
−15

−42
−26

−43
−27

−32
−3

NR
NR

Trial 2

Noninflammatory lesion, mean %
reduction from BL

Table 2  Efficacy data at week 12 for topical retinoid monotherapies approved by the US FDA for the treatment of acne as of April 21, 2020 for which prescribing information efficacy data in
facial acne are available
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Agent
Vehicle
Tretinoin gel
(Atralin)
0.05%a
Agent
Vehicle
Adapalene lotion
(Differin) 0.1%
Agent
Vehicle
Tazarotene foam
(Fabior) 0.1%l
Agent
Vehicle
Tretinoin lotion
(Altreno)
0.05%l
Agent
Vehicle
Trifarotene
cream (Aklief)
0.005%m
Agent
Vehicle
Tazarotene
lotion (Arazlo)
0.045%l
Agent
Vehicle

Retinoid

December 18,
2019

October 4, 2019

August 23, 2018

May 11, 2012

March 17, 2010

July 26, 2007

Approval date

Table 2  (continued)

29.6i
17.3i

25.5i
13i

397
404

402
411

42.3k
25.7k

29.4k
19.5k

602
610

612
596

19.8i
12.5i

16.5i
6.9i

413
407

406
414

28k
13k

29k
16k

373
369

371
372

24.1j
16.4j

26.3j
17.3j

535
531

533
542

23i
14i

21h
12h

299
302

375
185

NR
NR

21b
9b

NR
NR

258
134

Trial 2

Trial 1

Trial 1

Trial 2

Success (%)

N

−55.5
−45.7

−54.4
−44.8

−50.9
−40.4

−58
−45

−54.9
−40.3

−41
−26

−51.6
−40.7

Trial 1

−59.5
−49

−66.2
−51.2

−53.4
−41.5

−55
−45

−46.0
−36.9

−30
−17

NR
NR

Trial 2

Inflammatory lesion, mean %
reduction from BL

−51.4
−41.5

−49.7
−35.7

−47.5
−27.3

−55
−33

−49.6
−35.7

−43
−21

−39.7
−27.2

Trial 1

−60
−41.6

−57.7
−43.9

−45.6
−31.9

−57
−41

−43.1
−30.2

−37
−20

NR
NR

Trial 2

Noninflammatory lesion, mean %
reduction from BL
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Studies were in patients with moderate facial and truncal acne; data shown are for facial acne

m

Defined as 0 (clear) or 1 (almost clear) with a ≥ 2 grade reduction from baseline by IGA

Studies were in patients with moderate-to-severe acne

l

Defined as ≥ 2-point reduction from baseline on a 5-point IGA scale (definition from Eichenfield et al. 2010) [75]

k

j

Defined as 0 (clear) or 1 (very mild) by EGSS

Defined as 0 (clear) or 1 (almost clear/very mild) with ≥ 2 grade reduction from baseline by EGSS

i

Median values

h

Defined as no or minimal acne/no, minimal, or mild acne

g

f

N values are for lesion count data. For 12-week global improvement, in Trial 1 agent and vehicle N values are 105 and 117, respectively; in Trial 2 they are 117 and 110, respectively

Defined as improvement of ≥ 75%

e

Defined as achieving ‘an excellent result’

d

Defined as ‘clear’ or ‘almost clear’ by IGA

c

Patients had mild-to-moderate acne

b

a

BL baseline, EGSS Evaluator’s Global Severity Score, FDA US Food and Drug Administration, IGA Investigator’s Global Assessment, NR not reported

Acne severity is noted if details were provided in the label. Discontinued formulations are not listed (Source: www.accessdata.fda.gov/scripts/cder/daf/)

Retin-A (tretinoin) creams (0.1%, 0.05%, 0.025%) and gels (0.025%, 0.01%) have no original labels with data on the US FDA site and are therefore not included here; the 0.025% gel formulation
was later produced under the brand name Avita and data for that product are listed above

Table 2  (continued)
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and noninflammatory lesions (46% vs 30%; p < 0.001), in
treatment success (18% vs 9%; p < 0.001), and in patient
satisfaction (53% vs 43%; p < 0.001). Application-site
pain, dryness, and erythema, all mostly mild or moderate,
were reported in 3.1%, 3.7%, and 1.4% of tretinoin 0.05%
lotion patients, respectively. This tretinoin 0.05% lotion formulation received FDA approval for acne in August 2018
(Table 2; Fig. 1).
Polymeric emulsion technology has also been applied
to tazarotene to improve its tolerability. It provides for the
simultaneous release of the retinoid along with emollients
and humectants from a 3-D mesh matrix (Fig. 2c, parts 1
and 2), potentially allowing the use of lower drug concentrations while maintaining efficacy [70]. This theory was put
to the test in a phase II, multicenter, double-blind, vehiclecontrolled study of a novel tazarotene 0.045% polymeric
lotion and commercially available tazarotene 0.1% cream
[71]. Among the 210 patients with moderate-to-severe acne
randomized to the three arms, the tazarotene 0.045% lotion
proved superior to vehicle in reducing lesion counts and
improving clinical success. At less than half the concentration of the tazarotene 0.1% cream, the novel formulation
proved numerically more effective in reducing inflammatory
(63.8% vs 60.0%) and noninflammatory (56.9% vs 54.1%)
lesions and had a higher rate of treatment success (18.8%
vs 16.7%) at week 12; these comparisons, however, did not
reach statistical significance. Application-site pain (2.9%
vs 4.2%), erythema, exfoliation, and dryness (0% vs 1.4%
for each) were less frequent in patients treated with tazarotene 0.045% lotion than tazarotene 0.1%; furthermore, no
patients treated with tazarotene 0.045% lotion discontinued
treatment due to AEs. A pooled analysis of two identical
phase III, double-blind, randomized, vehicle-controlled studies of tazarotene 0.045% lotion versus vehicle confirmed its
statistically significant superiority to vehicle [72]. Among
AEs deemed treatment-related, the most common in the
tazarotene 0.045% lotion arm were application-site pain
(5.3%), dryness (3.6%), exfoliation (2.1%), and erythema
(1.8%). There were 13 (1.8%) and 6 (0.8%) discontinuations
in the tazarotene arm due to application-site pain and erythema, respectively. Tazarotene 0.045% lotion received FDA
approval for use in the topical treatment of acne in December
2019 (Table 2; Fig. 1).

5 Conclusions
In the 50 years since the initial approval of tretinoin, topical
retinoids—alone or in combination with other agents—have
become the mainstay of acne treatment and have provided
treatment options for other dermatological indications not
addressed herein. Studies have shown, however, that adherence to these widely prescribed agents in acne vulgaris is
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◂Fig 2  Retinoid formulations. a Microsponge. Adapted from Embil

and Nacht, 1996 [64]. Scanning electron micrograph of a microsponge particle approximately 25 microns in diameter (×5000). Inset:
The ultrastructure of a fractured microsponge (×6000). b Micronized tretinoin [62]. Cryo scanning electron microscopy imaging
of the polymeric matrix (×1000). Micronized tretinoin particles are
predominantly < 10 microns in diameter. c Polymeric emulsion (for
tazarotene) [70]. Part 1: Cryo-scanning electron microscopy imaging
showing oil-in-water emulsion droplet (approximately 1- to 2-micron
diameter) separated within a polymeric matrix (×10,000). Part 2:
This highly spreadable lotion formulation was developed to allow for
even skin distribution and more efficient delivery of tazarotene into
dermal layers while reducing the potential for skin irritation

remarkably low, with perhaps 30% of prescriptions never
filled [55], and almost one-half of all patients poorly adherent with the prescribed regimen [50, 58]. The local irritation
associated with topical retinoids, which is most prominent
in the first few weeks of therapy, has been associated with
poor adherence [53, 54]. Among the avenues explored to
minimize irritation and maximize adherence, neither the
theory that irritancy inherently paralleled efficacy for topical
retinoids nor the idea that adverse events were due to insufficient retinoid receptor subtype selectivity have proven to be
true. Half a century of research has resulted in new generations of retinoids with improved stability (primarily through
structural modification) and greater tolerability (largely a
result of improved formulation technologies).
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